CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

While the fear of cancer looms large in the minds of many, the condition's vague indicators make it hard to know when genuine ...

A new mum put her symptoms of fatigue and breathlessness down to pregnancy. But tests finally revealed the devastating ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline growth drivers.

Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

That being said, we’re here with a list of the 10 most profitable new stocks to buy now. We sifted through the Finviz stock screener to compile a list of the top companies that went public in the last ...

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

The trial will include patients with non-small cell lung, colorectal, head and neck, and cutaneous cancers with EGFR amplification.

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...